US FDA’s Marks Was Frustrated About Slow Completion Of 2021 Comirnaty Review
Executive Summary
CBER Director Peter Marks told Janet Woodcock in an email that he thought reviewers were treating the BLA for the first fully approved COVID-19 vaccine as a conventional review or learning exercise.
You may also be interested in...
Quick And Flexible Vaccine Approval Must Include Postmarket Simplicity, US FDA’s Kaslow Says
After making the COVID-19 vaccines available, multiple presentations based on age and vaccination status created confusion that likely hindered uptake, said OVRR Director David Kaslow.
House Lawmakers Could Receive A Mountain Of Docs On US FDA Scientific Disagreements
The request from House Energy and Commerce Committee Republicans states they are worried about retaliation against career agency staff.
CBER Director Marks’ Intervention On Sarepta Gene Therapy Filing Decision Appears To Backfire
Former OTAT Director Wilson Bryan says Peter Marks’ order to file Sarepta’s DMD gene therapy application was mainly a public relations move, which does not seem to have worked in the FDA’s favor. Upcoming advisory committee could now involve as much scrutiny of the agency as the application itself.